Our findings showed that treatment with TGF-β1 resulted in comparable enhancements in radioresistance in CRC cells exposed to CAFS-CM, similar to those treated with CAFR-CM (Fig. 6C–F). Here, TGFB1 is linked to colorectal carcinoma.